George Nolen, Recently Retired CEO of Siemens Corporation, Joins InVivo Therapeutics Board of Directors

George Nolen, Recently Retired CEO of Siemens Corporation, Joins InVivo Therapeutics Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Corporation has added George Nolen, former President and Chief Executive Officer of Siemens Corporation, to its Board of Directors. The Board approved the appointment on Friday, December 11th.

InVivo Therapeutics Chief Executive Officer Frank Reynolds is looking forward to reuniting with Nolen. During Reynolds' time at Siemens, Nolen was his mentor in the high potential candidate pool.

Said Reynolds, "I had a rare opportunity to develop under a world-class business executive, and I continue to utilize George's wisdom and knowledge in my business decisions on a daily basis." Reynolds is confident that the knowledge and experience that Nolen has gained over a 26-year career with Siemens will be beneficial to InVivo's continued development and anticipated rapid growth.

"I'm very excited to be part of something that will help so many people around the world and provide some relief for the enduring suffering caused by spinal cord injuries," said Nolen. "At Siemens I observed Frank's success and I look forward to helping to guide InVivo's success as we advance InVivo's technologies to market".

At Siemens USA, Nolen was responsible for $22.4 Billion in revenue and 69,000 employees. He was active in the Business Roundtable where he served on the BRT's Consumer, Health and Retirement committee and the Sustainable Growth Committee. Prior to becoming CEO of Siemens in 2004, he had served as President of Siemens' Information and Communications division from 1998 to 2004.

Nolen is currently active on the Board and Executive Committee of the U.S. Chamber of Commerce as well as on the Virginia Tech Board of Visitors. He also serves as the Chairman of the Virginia Bioinformatics Institute.

InVivo Therapeutics Corporation is a Cambridge, MA medical device company focused on combining polymers and stem cells to restore function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of research initiated in the laboratories of Robert Langer, PhD, of the Massachusetts Institute of Technology, Jay Vacanti, MD, of the Massachusetts General and Children's Hospitals in Boston, and Yang Teng, PhD, MD, of Harvard's Brigham and Women's Hospital.

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.